Emcure Pharmaceuticals Limited — Febuxostat Exporter Profile
Indian Pharmaceutical Exporter · #6 for Febuxostat · $2.0M export value · DGFT Verified
Emcure Pharmaceuticals Limited is the #6 Indian exporter of Febuxostat with $2.0M in export value and 52 verified shipments. Emcure Pharmaceuticals Limited holds a 4.1% market share in Febuxostat exports across 7 countries. The company exports 39 pharmaceutical products worth $147.8M across 19 therapeutic categories.
Emcure Pharmaceuticals Limited — Febuxostat Export Profile: Buyers & Destinations
Where Does Emcure Pharmaceuticals Limited Export Febuxostat?
| Country | Value | Shipments | Share |
|---|---|---|---|
| CANADA | $1.1M | 27 | 80.7% |
| UNITED KINGDOM | $201.8K | 20 | 14.4% |
| MYANMAR | $52.3K | 4 | 3.7% |
| TANZANIA | $10.3K | 2 | 0.7% |
| ZIMBABWE | $4.1K | 2 | 0.3% |
| MAURITIUS | $1.7K | 2 | 0.1% |
| MALTA | $4 | 1 | 0.0% |
Emcure Pharmaceuticals Limited exports Febuxostat to 7 countries. The largest destination is CANADA accounting for 80.7% of Emcure Pharmaceuticals Limited's Febuxostat shipments, followed by UNITED KINGDOM (14.4%) and MYANMAR (3.7%). These destinations reflect Emcure Pharmaceuticals Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Febuxostat from Emcure Pharmaceuticals Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| MARCAN PHARMACEUTICALS INC | CANADA | $600.0K | 12 |
| MARCAN PHARMACEUTICALS INC. | CANADA | $357.6K | 8 |
| MARCAN PHARMACEUTICALS INC., | CANADA | $170.5K | 4 |
| TILLOMED LABORATORIES LTD | UNITED KINGDOM | $122.3K | 10 |
| TILLOMED LABORATORIES LIMITED | UNITED KINGDOM | $79.6K | 7 |
| NI NI MYO MYO COMPANY LIMITED | MYANMAR | $28.1K | 2 |
| KHETAN COMPANY LIMITED | MYANMAR | $24.2K | 2 |
| PHILLIPS PHARMACEUTICALS(TANZANIA) | TANZANIA | $10.3K | 2 |
| NEW AVAKASH INTERNATIONAL | ZIMBABWE | $4.1K | 2 |
| THE MAURITIUS PHARMACY SEEGOBIN | MAURITIUS | $1.7K | 2 |
Emcure Pharmaceuticals Limited supplies Febuxostat to 15 buyers globally. The largest buyer is MARCAN PHARMACEUTICALS INC (CANADA), followed by MARCAN PHARMACEUTICALS INC. (CANADA) and MARCAN PHARMACEUTICALS INC., (CANADA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Febuxostat Export Value and How Much Does Emcure Pharmaceuticals Limited Contribute?
India exported $24.2M worth of Febuxostat through 3,494 shipments from 182 suppliers to 91 countries, serving 421 buyers globally. Emcure Pharmaceuticals Limited contributes $2.0M to this total, accounting for 4.1% of India's Febuxostat exports. Emcure Pharmaceuticals Limited ships Febuxostat to 7 countries through 15 buyers.
What Is the Average Shipment Value for Emcure Pharmaceuticals Limited's Febuxostat Exports?
Emcure Pharmaceuticals Limited's average Febuxostat shipment value is $38.7K per consignment, based on 52 shipments totaling $2.0M. The largest destination is CANADA (80.7% of Emcure Pharmaceuticals Limited's Febuxostat exports).
How Does Emcure Pharmaceuticals Limited Compare to Other Indian Febuxostat Exporters?
Emcure Pharmaceuticals Limited ranks #6 among 182 Indian Febuxostat exporters with a 4.1% market share. The top 3 exporters are MSN LABORATORIES PRIVATE LIMITED ($6.0M), AJANTA PHARMA LIMITED ($4.5M), ALEMBIC PHARMACEUTICALS LIMITED ($2.8M). Emcure Pharmaceuticals Limited processed 52 shipments to 7 destination countries.
What Febuxostat Formulations Does Emcure Pharmaceuticals Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| MAR FEBUXOSTAT TABLETS 80MG 100T CA | $450.0K | 9 |
| MAR-FEBUXOSTAT TABLETS 80MG 100T CA BATC | $149.1K | 3 |
| MAR-FEBUXOSTAT TABLETS 80MG 100T CA,BATC | $50.0K | 1 |
| MAR-FEBUXOSTAT TABLETS 80MG 100T CA PACK SIZE 1X100T BATCH NO:H232003A MANUFACTURING :SEP-2023 EXP:AUG-2026 | $50.0K | 1 |
| MAR-FEBUXOSTAT TABLETS 80MG 100T CA PACK SIZE 1X100T BATCH NO:H232002 MANUFACTURING :SEP-2023 EXP:AUG-2026 | $50.0K | 1 |
| MAR-FEBUXOSTAT TABLETS 80MG 100T CA BATCH NO:H232001 | $50.0K | 1 |
| FEBUXOSTAT TABLETS 80MG 100T CA-MAR (PACK SIZE 1X100T) BATCH NO:H240046A MFG:JAN-2024 EXP:DEC-2026NOS | $50.0K | 1 |
| FEBUXOSTAT TABLETS 80MG 100T CA-MAR (PACK SIZE 1X100T) BATCH NO:H241002 MFG:MAY-2024 EXP:APR-2027 | $50.0K | 1 |
| FEBUXOSTAT TABLETS 80MG 100T CA-SANIS (PACK SIZE 1X100T) BATCH NO:H241004 MFG:MAY-2024 EXP:APR-2027 | $50.0K | 1 |
| FEBUXOSTAT TABLETS 80MG 100T CA-MAR (PACK SIZE 1X100T) BATCH NO:H241002 MFG:MAY-2024 EXP:APR-20274856NOS15.5 | $50.0K | 1 |
Emcure Pharmaceuticals Limited exports 46 distinct Febuxostat formulations including tablets, capsules, syrups, and combination drugs. The top formulation is MAR FEBUXOSTAT TABLETS 80MG 100T CA with 9 shipments worth $450.0K.
Regulatory Requirements: Exporting Febuxostat to Key Markets
What Emcure Pharmaceuticals Limited must comply with to export Febuxostat to its top destination countries
Canada — HC
Approval Process
ANDS (Abbreviated New Drug Submission) referencing Canadian Reference Product. Comparative bioavailability study required.
Timeline: 12–18 months
GMP & Export Requirements
Health Canada GMP (GUI-0001); Drug Establishment Licence (DEL) inspection
Drug Identification Number (DIN) for each product; Certificate of Pharmaceutical Product from CDSCO
Note: Subject to Good Import Practices and annual C.01.014.6 review.
United Kingdom — MHRA
Approval Process
Post-Brexit UK Marketing Authorisation via national procedure. Separate from EU approval since January 2021.
Timeline: 12–15 months
GMP & Export Requirements
UK GMP compliance; MHRA inspection of manufacturing site
Manufacturer Import Authorisation (MIA) held by UK importer; Qualified Person (QP) batch release
Note: Post-Brexit: EU GMP certificates no longer automatically valid in UK. Separate MHRA recognition required.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Emcure Pharmaceuticals Limited Compare to Nearest Febuxostat Exporters?
Exporters ranked immediately above and below #6 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 3 | ALEMBIC PHARMACEUTICALS LIMITED | $2.8M | 56 | 1 | $50.0K |
| 5 | MACLEODS PHARMACEUTICALS LTD | $2.1M | 68 | 12 | $31.5K |
| 6 | EMCURE PHARMACEUTICALS LIMITED ★ | $2.0M | 52 | 7 | $38.7K |
| 4 | LUPIN LIMITED | $1.5M | 30 | 2 | $50.0K |
| 7 | WATSON PHARMA PRIVATE LIMITED | $1.1M | 21 | 2 | $50.0K |
Emcure Pharmaceuticals Limited ranks #6 among 182 Indian Febuxostat exporters. Average shipment value of $38.7K compared to the market average of $132.8K. The closest competitors by value are ALEMBIC PHARMACEUTICALS LIMITED and MACLEODS PHARMACEUTICALS LTD.
Which Indian Ports Ship Febuxostat Exports?
| Port | Shipments | % Share |
|---|---|---|
| DELHI AIR CARGO ACC (INDEL4) | 639 | 18.3% |
| SAHAR AIR | 615 | 17.6% |
| DELHI AIR | 387 | 11.1% |
| SAHAR AIR CARGO ACC (INBOM4) | 351 | 10.0% |
| NHAVA SHEVA SEA (INNSA1) | 145 | 4.1% |
| HYDERABAD ICD (INSNF6) | 98 | 2.8% |
| HYDERABAD AIR | 96 | 2.7% |
| Bombay Air | 84 | 2.4% |
What Other Lipid & Metabolism Products Does Emcure Pharmaceuticals Limited Export?
Emcure Pharmaceuticals Limited also exports these lipid & metabolism products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Emcure Pharmaceuticals Limited's Febuxostat Exports
Emcure's extensive export operations are influenced by various geopolitical factors. The Israel-Iran tensions have led to disruptions in Red Sea shipping routes, increasing shipping costs and transit times for Indian exporters. This situation necessitates strategic adjustments in logistics and supply chain management to mitigate potential delays and cost escalations.
Conversely, the ongoing US-China trade tensions have opened opportunities for Indian pharmaceutical companies like Emcure to expand their footprint in the US market. The US's inclination to diversify its supply chain away from China presents a favorable environment for Indian exporters to increase their market share.
In the European Union, stringent regulatory changes, such as the Falsified Medicines Directive, impose additional compliance requirements on exporters. Emcure's adherence to these regulations is crucial for maintaining and expanding its presence in the EU market.
Emcure Pharmaceuticals Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards is paramount for Emcure's export operations. The company has consistently met the Good Manufacturing Practice (GMP) requirements set by the FDA, WHO, and EU authorities. However, the evolving regulatory landscape demands continuous investment in quality assurance and compliance mechanisms to ensure uninterrupted market access.
Recent incidents, such as the brief shutdown of the Pune plant due to a fire, highlight the importance of robust risk management and compliance strategies to maintain operational continuity and regulatory adherence. (tipranks.com)
About Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited exports 39 products worth $147.8M. Beyond Febuxostat, top products include Dolutegravir, Mycophenolate, Tenofovir, Iron, Melphalan. View the complete Emcure Pharmaceuticals Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Febuxostat — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Febuxostat shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Emcure Pharmaceuticals Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 58 individual customs records matching Emcure Pharmaceuticals Limited exporting Febuxostat, covering 46 formulations to 7 countries via 15 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 91+ countries, 421+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Febuxostat Export Data from Emcure Pharmaceuticals Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Emcure Pharmaceuticals Limited's Febuxostat exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Emcure Pharmaceuticals Limited
Full Company Profile →
39 products · $147.8M total trade · 19 categories
Febuxostat Stats
Company Overview
Top Products by Emcure Pharmaceuticals Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Emcure Pharmaceuticals Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Febuxostat. For current shipment-level data, contact TransData Nexus.